Nyxoah (NYXH) said Tuesday it is actively addressing the validation of a process used with a component of its Genie obstructive sleep apnea treatment device at its US manufacturing site ahead of potential US Food and Drug Administration marketing approval.
The company said it is confident of completing the validation in the near term, with the application approval likely in Q2.
The FDA late last month issued an approvable letter with regard to Genio's pre-market approval application.
Nyxoah shares were up nearly 23% in recent premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。